Pfizer Inc
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).
Did you know?
Free cash flow has been growing at -2.5% annually.
Current Price
$26.67
-0.49%GoodMoat Value
$17.95
32.7% overvaluedProfile
Valuation (TTM)
Market Cap$151.64B
P/E19.52
EV$203.41B
P/B1.75
Shares Out5.69B
P/Sales2.42
Revenue$62.58B
EV/EBITDA14.39
Pfizer Inc (PFE) Stock Analysis
GoodMoat Analysis
Pfizer is a global pharmaceutical giant facing a post-pandemic transition, with its moat primarily based on patents and scale. The stock trades at a significant premium to the GoodMoat target price, indicating an unfavourable valuation. The combination of a weak moat score and high valuation suggests it fails the initial gates of the investment framework.
Read full analysis
Pfizer Inc. is a global pharmaceutical leader that discovers, develops, and commercializes medicines and vaccines, most notably its COVID-19 products. Its primary competitive advantages, assessed through the GoodMoat framework, are likely in Regulatory Barriers (patents) and Scale Privilege in manufacturing and R&D. However, the company scores poorly on other moat criteria such as Low Disruption Risk, Pricing Power in the face of generic competition, and Network Effects. With a likely Moat Score below the critical threshold of 5, it fails the first gate of the Decision Framework. Financially, the company shows strain with a -1.2% YoY revenue decline, a 12.4% profit margin, and an ROE of 9.0%, which is below the 15-20% high-quality benchmark. While the dividend yield of 6.30% is high, the valuation is a key concern. The current price of $27.44 is approximately 53% above the GoodMoat target of $17.95, suggesting a deeply unfavourable margin of safety. This significant overvaluation, combined with the weak underlying business quality and growth trajectory, makes further investigation from a traditional value perspective unfavourable unless a compelling thesis for a durable post-COVID turnaround emerges.
Market Cap$151.64B
Current Price$26.67
P/E Ratio19.52
Forward P/E—
PEG Ratio-0.04
EPS$1.36
Book Value$15.21
P/B Ratio1.75
PFE Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use -2.5% FCF growth (CAGR)
Cash vs Debt
Net Debt: 63.7B
Revenue
40.9B
FY19
41.7B
FY20
81.3B
FY21
101.2B
FY22
59.6B
FY23
63.6B
FY24
62.6B
FY25
Net Income
16.0B
FY19
9.2B
FY20
22.0B
FY21
31.4B
FY22
2.1B
FY23
8.0B
FY24
7.8B
FY25
PFE 52-Week Range
$20.92
$28.55
50-Day MA: $27.23200-Day MA: $25.16
Did you know?
Free cash flow has been growing at -2.5% annually.
Pfizer Inc (PFE) Financial Summary
Pfizer Inc (PFE) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. The stock currently trades at $26.67 with a market capitalization of $151.64B.
Key valuation metrics include a P/E ratio of 19.52, price-to-book ratio of 1.75, and EPS of $1.36. The company reports a profit margin of 12.4% and return on equity of 9.0%.
PFE Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $151.64B |
| P/E Ratio | 19.52 |
| EPS | $1.36 |
| P/B Ratio | 1.75 |
| P/S Ratio | 2.42 |
| EV/EBITDA | 14.39 |
| Dividend Yield | 6.44% |
| Profit Margin | 12.4% |
| Return on Equity | 9.0% |
| Debt/Equity | 0.75 |
PFE Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $40.91B | $16.03B |
| FY20 | $41.65B | $9.16B |
| FY21 | $81.29B | $21.98B |
| FY22 | $101.17B | $31.37B |
| FY23 | $59.55B | $2.12B |
| FY24 | $63.63B | $8.03B |
| FY25 | $62.58B | $7.77B |
Pfizer Inc (PFE) Valuation
Based on GoodMoat's DCF model, Pfizer Inc has a fair value estimate of $17.95. At the current price of $26.67, the stock appears 48.5% overvalued relative to our intrinsic value estimate.
PFE Quality Indicators
Pfizer Inc maintains a profit margin of 12.4% and an operating margin of 12.0%. Return on equity stands at 9.0%. The current ratio is 1.16. Debt-to-equity ratio is 0.75.
About Pfizer Inc
At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and multispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world's most common cancers, including breast cancer, gastrointestinal cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About the Pfizer, Astellas and Merck Collaboration Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Seagen and Astellas entered a clinical collaboration agreement with Merck to evaluate the combination of Seagen's and Astellas' PADCEV™ (enfortumab vedotin) and Merck's Keytruda ® (pembrolizumab) in patients with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin-based chemotherapy. Pfizer Inc. successfully completed its acquisition of Seagen on December 14, 2023. Keytruda is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada).
PFE Free Cash Flow
Pfizer Inc generated $9.07B in trailing twelve-month free cash flow, representing an FCF yield of 5.98%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
PFE Shares Outstanding
Pfizer Inc has 5.69 billion shares outstanding at a share price of $26.67, giving it a market capitalization of $151.64B.